The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Phase I study of telisotuzumab adizutecan in advanced pancreatic cancer
James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase I basket study (NCT06084481) of telisotuzumab adizutecan (Temab-A), a c-Met–targeting antibody-drug conjugate (ADC), in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Temab-A demonstrated promising antitumor activity, particularly in pre-treated patients previously, with an overall manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As we know, CMET is expressed across a variety of solid tumors and is implicated in a variety of processes like tumor progression, metastasis, and treatment resistance. Telisotuzumab adizutecan or Temab-A is an antibody drug conjugate that has shown preliminary safety and efficacy in a variety of solid tumors. We know that pancreatic ductal adenocarcinoma expresses MET and is sensitive to topo-1 inhibitors...
As we know, CMET is expressed across a variety of solid tumors and is implicated in a variety of processes like tumor progression, metastasis, and treatment resistance. Telisotuzumab adizutecan or Temab-A is an antibody drug conjugate that has shown preliminary safety and efficacy in a variety of solid tumors. We know that pancreatic ductal adenocarcinoma expresses MET and is sensitive to topo-1 inhibitors. So we conducted a phase one basket study of Temab-A across solid tumors. And at this meeting in Berlin, we presented the pancreatic ductal adenocarcinoma cohort. We enrolled 42 patients over the course of the study. We observed that the confirmed objective response rate was a 23.8%. We observed that depending on prior line of treatment, this was a second line study, the response was variable. So in 26 patients that got prior FOLFIRINOX, the response rate was 15%. In the remainder of patients that got prior Gemcitabine-Paclitaxel, the response rate was 40 percent. The safety profile was generally manageable and our conclusion was certainly that tisotizumab vedotin should be explored further in pancreatic ductal adenocarcinoma and of course we’re looking forward to upcoming results from the remainder of those cohorts.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
